CAHC provided comments to the Office of the United States Trade Representative (USTR) regarding the request for comment pursuant to the Executive Order titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
CAHC urged for continued collaboration and thoughtful policy development to ensure American patients are not unfairly burdened with the costs of global pharmaceutical research and development.
Download Resource